Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. méd. Chile ; 133(1): 71-76, ene. 2005. tab
Artigo em Espanhol | LILACS | ID: lil-398018

RESUMO

Background: An important loss of bone mineral density, associated to pain and fractures, has been reported in children with acute lymphoblastic leukemia (ALL). Aim: To measure bone mineral density among children with acute lymphoblastic leykemia (ALL) that completed the remission induction phase with chemotherapy, that lasts 30 days. Patients and methods: children with ALL, admitted to the oncology unit of a general hospital were considered eligible for the study. body composition and bone mineral density were measured by dual energy x ray absorptiometry (DEXA). each child with ALL was paired with a healthly control. Results: Fourteen children age 1 to 11 years, completed the study, Spine and femoral bone mineral desities were significantly lower than in their matched controls. No differences in total body bone mineral density or content were observed. Children with ALL had a lower fat free mass and a higher fat mass than their matched controls. There was a significant correlation between fat free mass and bone mineral content. Conclusions: After one month of chemotherapy, children with ALL had a lower bone mineral density in the spine and femur and a lower fat free mass.


Assuntos
Masculino , Humanos , Feminino , Lactente , Pré-Escolar , Criança , Densidade Óssea , Leucemia-Linfoma Linfoblástico de Células Precursoras/fisiopatologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Absorciometria de Fóton , Estudos Transversais , Estudos de Casos e Controles , Fatores de Tempo
2.
Rev. chil. obstet. ginecol ; 70(5): 340-345, 2005.
Artigo em Espanhol | LILACS | ID: lil-449848

RESUMO

El objetivo de este documento es entregar una guía práctica de tratamiento del climaterio, debido a la confusión producida por el estudio WHI en 2002. La TH debe ser solo utilizada cuando exista una indicación clara para su uso. La paciente sintomática es la principal beneficiada del tratamiento. No existe un tratamiento alternativo a los estrógenos o estrógeno/progestina tan eficaz en el alivio de la sintomatología y en reducción de fracturas. La indicación de un tratamiento prolongado debe ser revisada anualmente.


Assuntos
Humanos , Feminino , Menopausa , Terapia de Reposição Hormonal/efeitos adversos , Terapia de Reposição Hormonal/normas , Climatério , Estrogênios/administração & dosagem , Guias de Prática Clínica como Assunto , Progestinas/administração & dosagem , Cloridrato de Raloxifeno/administração & dosagem , Terapia de Reposição Hormonal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA